Application of ITPRIPL1 as gastric cancer diagnosis or prognosis biomarker
Using ITPRIPL1 as a biomarker has solved the problem of low sensitivity in the early diagnosis of gastric cancer, providing a new diagnostic and prognostic method. High expression levels of ITPRIPL1 can be used to identify poor prognosis, thus promoting the early diagnosis and immunotherapy of gastric cancer.
Patent Information
- Application Number
- CN202610322506.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-03-17
- Publication Date
- 2026-05-26
AI Technical Summary
Current technologies for early diagnosis of gastric cancer have low sensitivity, lack effective biomarkers, and are not effective in immunotherapy. New diagnostic and prognostic biomarkers are needed to improve treatment outcomes.
Using ITPRIPL1 as a biomarker, we detected the expression level of ITPRIPL1 in the tissues and cells of gastric cancer patients. We then used chips, test strips, or kits for diagnosis and prognostic analysis. Combined with qPCR, immunohistochemistry, and single-cell sequencing, we verified the association between high expression of ITPRIPL1 in gastric cancer and poor prognosis.
This study provides a novel biomarker for the diagnosis and prognosis of gastric cancer. High expression levels of ITPRIPL1 clearly indicate poor prognosis, promoting early diagnosis and immunotherapy for gastric cancer. It also verifies the correlation between high expression of ITPRIPL1 in gastric cancer tumor cells and the malignant phenotype and regulation of the immune microenvironment.